Subscribe
shutterstock_1335829340_manuel-esteban
manuelesteban / Shutterstock.com
20 April 2021Big PharmaRory O'Neill

Pfizer drops Xeljanz patent suits

Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration (FDA) of plans to launch their own version of Xeljanz XR (tofacitinib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pfizer’s pregabalin litigation: the latest twist
15 February 2023   The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Generics
Pfizer sues MSN Labs over Xeljanz generic
9 June 2022   Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Pfizer’s pregabalin litigation: the latest twist
15 February 2023   The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Generics
Pfizer sues MSN Labs over Xeljanz generic
9 June 2022   Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.

More on this story

Big Pharma
Pfizer’s pregabalin litigation: the latest twist
15 February 2023   The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
Big Pharma
Pfizer commits to offer drugs not-for-profit to 45 low-income countries
31 May 2022   Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.
Generics
Pfizer sues MSN Labs over Xeljanz generic
9 June 2022   Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility